Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biogen (NQ: BIIB)
345.22 USD  +2.29 (+0.67%)
Official Closing Price  /  Updated: 6:28 PM EDT, Aug 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 917,300
Open 341.00
Bid (Size) 330.00 (1)
Ask (Size) 346.50 (1)
Prev. Close 342.93
Today's Range 339.13 - 346.83
52wk Range 249.17 - 388.67
Shares Outstanding 211,007,945
Dividend Yield N/A
Performance
YTD
+3.31%
+3.31%
1 Month
-3.60%
-3.60%
3 Month
+24.33%
+24.33%
6 Month
+20.10%
+20.10%
1 Year
+22.52%
+22.52%
Top News
More News
New Research Coverage Highlights Texas Instruments, Biogen, Sanchez Energy, Amazon, Sirius XM, and JPMorgan Chase — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Texas Instruments... Read More
from GlobeNewswire News Releases
CORRECTED--Express Scripts staking out million dollar gene therapies
Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug... Read More
category companyNews
from Reuters: Company News
More News
Read More
RPT-FOCUS-Express Scripts staking out million dollar gene therapies
category companyNews
from Reuters: Company News
RPT-FOCUS-Express Scripts staking out million dollar gene therapies
category companyNews
from Reuters: Company News
FOCUS-Express Scripts staking out million dollar gene therapies
category companyNews
from Reuters: Company News
Biogen's pricey muscle drug Spinraza too costly for Britain
category companyNews
from Reuters: Company News
Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate
category Market News , BIIB , Price Target , and 6 more.
from Benzinga
Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses
category PFE , AKCA , IONS , and 3 more.
from Motley Fool
There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong
category BIIB , Company Announcements , Biotechnology , and 11 more.
from MarketWatch
Biotech ETFs In Focus On String Of Q2 Earnings Beats
category Pharma/Biotech , Stocks / Equities , ETFs
from Blogs - TalkMarkets
CORRECTED-RPT-FOCUS-Eisai/Biogen to advance Alzheimer's drug, provide fresh hope
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More

© Copyright FinancialContent Services, Inc.
Terms and Conditions Privacy Policy Contact Us twitter linkedin twitter

Contact Us

(888) 688-9880

Services

Financial Widgets Financial Pages Web Services Consulting Financial Calculations Stock Data for Excel Newspaper Services For Advertisers Monetization Services Content Syndication Press Release Syndication

Services by Industry

Online Media Financial Services Newspaper Investor Relations Financial Blog Corporate Intranets Digital Signage Television Android Developers iOS Developers Wire Services Radio

About Us

Overview Careers Management Team Latest News Newsletters

Support

Support Articles Report an issue